{"entity":{"id":"nct06994676","kind":"trial","name":"A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias","aka":[],"tldr":"A phase 1 trial of CBX-250 run by Crossbow Therapeutics, Inc., now recruiting.","summary":"A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias is a phase 1 interventional study registered as NCT06994676 by Crossbow Therapeutics, Inc., with 72 participants planned, started 2025-07-16. Conditions recorded: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia and Chronic Myeloid Leukemia. Interventions recorded: CBX-250.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06994676","url":"https://clinicaltrials.gov/study/NCT06994676"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","cmml","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cbx-250"],"companies":["crossbow-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06994676","phase":"1","setting":"CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias","sponsor":"Crossbow Therapeutics, Inc.","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06994676/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"cbx-250","kind":"drug","name":"CBX-250","route":"/drugs/cbx-250/"}],"company":[{"id":"crossbow-therapeutics","kind":"company","name":"Crossbow Therapeutics","route":"/companies/crossbow-therapeutics/"}]}}